A patient being treated with liposomal amphotericin B may develop a false elevation in serum inorganic phosphorus (pseudohyperphosphatemia).
Drug: liposomal amphotericin B (AmBisome)
Mechanism: alteration in the kinetic performance of the phosphomolybdate method that results in upward shift in phosphorus values
Clinical features:
(1) The patient is being treated with liposomal amphotericin B.
(2) The patient is noted to have hyperphosphatemia.
(3) Hyperphosphatemia did not exist prior to therapy with the amphotericin B.
(4) Abnormalities in calcium or other electrolytes are absent.
(5) Treatment of the sample with LipoClear or ultrafiltration corrects the abnormal serum phosphorus value.
(6) The serum inorganic phosphorus normalizes once the liposomal amphotericin B therapy is discontinued.
To read more or access our algorithms and calculators, please log in or register.
Specialty: Clinical Laboratory, Obstetrics & Gynecology, Cardiology, Emergency Medicine, Critical Care
ICD-10: ,
